Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers

Inclusion Criteria: * Female, Age between 18 to 45 years (inclusive). * Body mass index (BMI) of ≥18 and ≤28 kg/m2, body weight ≥45 kg. * With a history of sexual activity * Regular menstruation cycle (25 to 35 days, inclusive). * Normal sex hormone levels, or abnormalities deemed clinically insignificant by the investigator. * Reached the standard within the time window after receiving the down-regulated drug. * Agreed to take effective contraceptive measures during and 6 months after the end of the study period. * Willing to participate in this clinical trial, understanding the study procedures, and able to provide written informed consent. Exclusion Criteria: * History of ovarian hyperstimulation syndrome, or polycystic ovary syndrome, or ovarian enlargement or cysts not caused by polycystic ovary syndrome, or primary ovarian failure; history of hypothalamic or pituitary tumors; history of malignancy; History of thrombosis; or other diseases that considered to influence the study by the investigator. * Unexplained reproductive tract bleeding. * Thin-layer cytology examination deemed clinically significant by the investigator. * Vital signs, physical examination, 12-lead electrocardiogram, or laboratory examination deemed clinically significant by the investigator with. * Pregnancy or lactation period, or positive human chorionic gonadotropin (HCG) examination. * Known to be allergic to follicle-stimulating hormone (FSH), or gonadotropin-releasing hormone agonists (GnRH-…